Chronic migraine: Current pathophysiologic concepts as targets for treatment

Bert B. Vargas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic daily headache (CDH) affects approximately 4% of the population and exerts a significant degree of disability on its sufferers. Chronic migraine (CM) is a subset of CDH that represents migraine without aura occurring on 15 or more days per month for at least 3 months. Although numerous risk factors are associated with the development of CM, the pathophysiology governing its genesis is largely unknown. The role of neurotransmitters, such as glutamate, as well as disruptions of antinociceptive systems and structures, are implicated in CM and are supported by the fact that treatments targeting these abnormalities are effective.

Original languageEnglish (US)
Pages (from-to)64-66
Number of pages3
JournalCurrent Pain and Headache Reports
Volume13
Issue number1
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Migraine Disorders
Headache Disorders
Migraine without Aura
Neurotransmitter Agents
Glutamic Acid
Population

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Chronic migraine : Current pathophysiologic concepts as targets for treatment. / Vargas, Bert B.

In: Current Pain and Headache Reports, Vol. 13, No. 1, 2009, p. 64-66.

Research output: Contribution to journalArticle

@article{c6b729793d5a4d8b84872684958a027b,
title = "Chronic migraine: Current pathophysiologic concepts as targets for treatment",
abstract = "Chronic daily headache (CDH) affects approximately 4{\%} of the population and exerts a significant degree of disability on its sufferers. Chronic migraine (CM) is a subset of CDH that represents migraine without aura occurring on 15 or more days per month for at least 3 months. Although numerous risk factors are associated with the development of CM, the pathophysiology governing its genesis is largely unknown. The role of neurotransmitters, such as glutamate, as well as disruptions of antinociceptive systems and structures, are implicated in CM and are supported by the fact that treatments targeting these abnormalities are effective.",
author = "Vargas, {Bert B.}",
year = "2009",
doi = "10.1007/s11916-009-0013-1",
language = "English (US)",
volume = "13",
pages = "64--66",
journal = "Current Pain and Headache Reports",
issn = "1531-3433",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Chronic migraine

T2 - Current pathophysiologic concepts as targets for treatment

AU - Vargas, Bert B.

PY - 2009

Y1 - 2009

N2 - Chronic daily headache (CDH) affects approximately 4% of the population and exerts a significant degree of disability on its sufferers. Chronic migraine (CM) is a subset of CDH that represents migraine without aura occurring on 15 or more days per month for at least 3 months. Although numerous risk factors are associated with the development of CM, the pathophysiology governing its genesis is largely unknown. The role of neurotransmitters, such as glutamate, as well as disruptions of antinociceptive systems and structures, are implicated in CM and are supported by the fact that treatments targeting these abnormalities are effective.

AB - Chronic daily headache (CDH) affects approximately 4% of the population and exerts a significant degree of disability on its sufferers. Chronic migraine (CM) is a subset of CDH that represents migraine without aura occurring on 15 or more days per month for at least 3 months. Although numerous risk factors are associated with the development of CM, the pathophysiology governing its genesis is largely unknown. The role of neurotransmitters, such as glutamate, as well as disruptions of antinociceptive systems and structures, are implicated in CM and are supported by the fact that treatments targeting these abnormalities are effective.

UR - http://www.scopus.com/inward/record.url?scp=59149094977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59149094977&partnerID=8YFLogxK

U2 - 10.1007/s11916-009-0013-1

DO - 10.1007/s11916-009-0013-1

M3 - Article

C2 - 19126374

AN - SCOPUS:59149094977

VL - 13

SP - 64

EP - 66

JO - Current Pain and Headache Reports

JF - Current Pain and Headache Reports

SN - 1531-3433

IS - 1

ER -